サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1610030

非アルコール性脂肪性肝炎臨床試験市場規模、シェア、動向分析レポート：フェーズ別、試験設計別、地域別、セグメント別予測、2025年～2030年

Non-alcoholic Steatohepatitis Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
非アルコール性脂肪性肝炎臨床試験市場規模、シェア、動向分析レポート：フェーズ別、試験設計別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年11月12日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非アルコール性脂肪肝炎臨床試験市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の非アルコール性脂肪肝炎臨床試験市場規模は、2025～2030年にかけてCAGR 6.26％を記録し、2030年までに41億4,000万米ドルに達すると予測されています。

医療費の増加、肥満症例、非アルコール性脂肪肝炎（NASH）の流行がこの市場の成長を促進する要因です。COVID-19の大流行により、NASH患者を対象とした新薬臨床試験への登録は停止されたが、人々は仮想訪問のようなデータ収集方法の代替手段に移行しました。非アルコール性脂肪性肝炎は、肝臓に瘢痕化と損傷を引き起こす脂肪肝疾患です。

NASHにはFDAが承認した治療法はなく、極端な場合には患者が肝臓移植を必要とするまでに進行する可能性があります。NASHは糖尿病と同様、肥満や糖分の多い食事と関連しています。一部の製薬会社は、糖尿病治療がNASH患者の助けになるかどうかを試験しています。しかし、COVID-19の大流行は、患者のリクルートからIP投与、安全性モニタリング、データの完全性に至るまで、NASH臨床試験のあらゆる要素に一石を投じています。臨床研究モニターは出張できないので、遠隔電子モニタリングは従来のオンサイトモニタリングに代わる実行可能な方法です。モニターは、紙の郵便、電子メール（電子カルテへの直接アクセスが可能）、または遠隔モニタリングシステムによって、調査拠点から情報を受け取ることができます。

12月、FDAは製薬部門に対し、NASHの診断と進行のための改善されたバイオマーカーの開発と確認を促すガイダンスを発表しました。多くの面において、生検の障壁を乗り越えることは、NASHに対する一般的な認知度の低さに比べて重要です。だからこそ、製薬会社はこの患者の負担を軽減するための革新的技術（様々な画像診断技術など）に投資し、それらの進歩を臨床試験の適切なエンドポイントマーカーとして受け入れるよう、肯定的なデータでFDAを説得することが重要なのです。

非アルコール性脂肪性肝炎臨床試験市場レポートハイライト

  • フェーズIII試験が市場を独占し、2024年の総売上シェアの54.3%を占める。第III相試験は、新治療法の薬事承認申請前の有効性と安全性の確認に不可欠です。
  • 2024年には、新たな治療介入の評価への注目が高まっていることから、介入試験セグメントが市場を独占しました。さらに、NASHに対する単剤療法と併用療法の両方を含む新薬候補を試験する研究開発研究が増加しています。
  • 北米の非アルコール性脂肪性肝炎臨床試験市場は2024年に48.9%のシェアを占め、優位を占めました。この地域の成長は、先進的医療システム、大規模な患者人口、強力な研究インフラに起因しています。
  • アジア太平洋の非アルコール性脂肪肝炎臨床試験市場は、予測期間中に最も高いCAGRで成長すると予想されます。この成長の背景には、糖尿病や肥満などの代謝性疾患の有病率の増加があります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 非アルコール性脂肪肝炎臨床試験市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助的な市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 非アルコール性脂肪肝炎臨床試験市場：フェーズ、推定・動向分析

  • セグメントダッシュボード
  • 世界の非アルコール性脂肪肝炎臨床試験市場、フェーズ、変動分析
  • 非アルコール性脂肪肝炎臨床試験の規模と傾向の分析（フェーズ別、2018～2030年）
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 非アルコール性脂肪肝炎臨床試験市場： 研究設計、推定・動向分析

  • セグメントダッシュボード
  • 世界の非アルコール性脂肪肝炎臨床試験市場、研究設計変動分析
  • 非アルコール性脂肪肝炎臨床試験の規模と傾向の分析（研究設計別、2018～2030年）
  • 介入研究
  • 観察研究
  • 拡大アクセス研究

第6章 非アルコール性脂肪肝炎臨床試験市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業分類
  • 企業市況分析、2024年
  • 企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • Icon Plc
    • Laboratory Corporation of America
    • AbbVie Inc.
    • Cadila Healthcare Ltd.
    • Takeda Pharmaceuticals
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Gilead Sciences Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 Global Non-alcoholic Steatohepatitis Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Non-alcoholic Steatohepatitis Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 8 North America Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 11 Canada Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 Mexico Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 15 UK Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 16 UK Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 17 Germany Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Germany Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 France Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 20 France Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 21 Italy Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Italy Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 23 Spain Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Spain Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 25 Sweden Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 26 Sweden Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 27 Norway Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Norway Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 29 Denmark Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Denmark Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 31 India Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 32 India Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 33 China Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 34 China Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 35 Japan Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Japan Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 37 India Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 38 India Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 39 Australia Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Australia Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 41 Thailand Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Thailand Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 South Korea Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 44 South Korea Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 45 Brazil Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Brazil Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 47 Argentina Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 48 Argentina Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 51 UAE Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 52 UAE Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 53 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 54 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Non-alcoholic Steatohepatitis Clinical Trials, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 Global Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 Global Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 18 Global Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 19 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 20 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 21 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 22 North America Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 23 North America Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 24 North America Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 25 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 26 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 27 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 28 US Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 29 US Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 30 US Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 31 US Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 46 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 47 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 48 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 49 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 50 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 51 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 52 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 53 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 54 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 55 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 56 UK Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 57 UK Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 58 UK Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 59 UK Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 60 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 61 Germany Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 62 Germany Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 63 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 64 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 65 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 66 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 67 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 68 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 69 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 70 France Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 71 France Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 72 France Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 73 France Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 74 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 75 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 76 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 77 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 78 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 79 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 80 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 81 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 82 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 83 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 84 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 85 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 86 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 87 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 88 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 89 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 90 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 91 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 92 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 93 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 94 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 95 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 96 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 97 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 98 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 99 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 100 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 101 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 102 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 103 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 104 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 105 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 106 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 107 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 108 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 109 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 110 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 111 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 112 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 113 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 114 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 115 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 116 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 117 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 118 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 119 China Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 120 China Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 121 China Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 122 China Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 123 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 124 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 125 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 126 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 127 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 128 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 129 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 130 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 131 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 132 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 133 India Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 134 India Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 135 India Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 136 India Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 137 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 138 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 139 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 140 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 141 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 142 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 143 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 144 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 145 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 146 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 147 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 148 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 149 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 150 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 151 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 152 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 153 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 154 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 155 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 156 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 157 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 158 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 159 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 160 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 161 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 162 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 163 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 164 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 165 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 166 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 167 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 168 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 169 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 170 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 171 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 172 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 173 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 174 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 175 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 176 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 177 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 178 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 179 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 180 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 181 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 182 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 183 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 184 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 185 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 186 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 187 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 188 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 189 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 190 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 191 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 192 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 193 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 194 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 195 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 196 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 197 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 198 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 199 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 200 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 201 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 202 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 203 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 204 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 205 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 206 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 207 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 212 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 213 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-911-4

Non-alcoholic Steatohepatitis Clinical Trials Market Growth & Trends:

The global non-alcoholic steatohepatitis clinical trials market size is expected to reach USD 4.14 billion by 2030, registering a CAGR of 6.26% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising healthcare expenditure, cases of obesity, and prevalence of non-alcoholic steatohepatitis (NASH) are the factors driving the growth of this market. Due to the COVID-19 pandemic, enrollment in new drug clinical trials for NASH patients was halted, but people shifted to alternate means of data collecting methods, like virtual visits. Non-alcoholic Steatohepatitis is a fatty liver disease that causes scarring and damage to the liver.

NASH has no FDA-approved treatment and can proceed to the point where patients need a liver transplant in extreme situations. NASH, like diabetes, is linked to obesity and a high-sugar diet. Some pharmaceutical companies are testing whether diabetes drugs could help NASH patients. However, the COVID-19 pandemic has thrown a wrench into every element of NASH clinical trials, from patient recruiting to IP administration and safety monitoring to data integrity. As clinical research monitors are not allowed to travel, remote electronic monitoring is a viable alternative to traditional on-site monitoring. Monitors could receive information from research locations by paper mail, e-mail (allowing direct access to electronic medical records), or remote monitoring systems.

In December, the FDA issued guidance urging the pharmaceutical sector to develop and confirm improved biomarkers for the diagnosis and progression of NASH. In many aspects, getting past the biopsy barrier is significant compared to a lack of general awareness of NASH, that's why it is critical for pharmaceutical companies to invest in innovations (such as a variety of imaging techniques) to alleviate this patient burden, and then persuade the FDA with positive data to accept those advancements as appropriate end-point markers for clinical trials.

Non-alcoholic Steatohepatitis Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market, accounting for 54.3% of the total revenue share in 2024. Phase III trials are essential for confirming the efficacy and safety of new therapies before they can be submitted for regulatory approval.
  • The interventional studies segment dominated the market in 2024 owing to an increasing focus on evaluating new therapeutic interventions. Moreover, growing research and development studies to test novel drug candidates, including both monotherapies and combination therapies for NASH.
  • North America non-alcoholic steatohepatitis clinical trials market dominated and accounted for a 48.9% share in 2024. The growth in the region is attributed to the region's advanced healthcare system, large patient population, and strong research infrastructure.
  • The non-alcoholic steatohepatitis clinical trials market in Asia Pacific is expected to grow at the highest CAGR over the forecast period. The growth can be attributed to the increasing prevalence of metabolic disorders, such as diabetes and obesity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Non-alcoholic Steatohepatitis Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pharmaceutical R&D Investment
      • 3.2.1.2. Rising Diabetic Population & Obesity
      • 3.2.1.3. Rising Healthcare Expenditure
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of Awareness
      • 3.2.2.2. Barriers to Enrolment
      • 3.2.2.3. Lethargic Drug Approval Process
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Non-alcoholic Steatohepatitis Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-alcoholic steatohepatitis clinical trials Market; Phase Movement Analysis
  • 4.3. Global Non-alcoholic Steatohepatitis Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-alcoholic Steatohepatitis Clinical Trials Market; Study Design Movement Analysis
  • 5.3. Global Non-alcoholic steatohepatitis clinical trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Clinical Trials Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. North America
    • 6.3.1. North America Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Competitive scenario
      • 6.3.2.3. Regulatory framework
      • 6.3.2.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Competitive scenario
      • 6.3.3.3. Regulatory framework
      • 6.3.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Competitive scenario
      • 6.3.4.3. Regulatory framework
      • 6.3.4.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Competitive scenario
      • 6.4.2.3. Regulatory framework
      • 6.4.2.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Competitive scenario
      • 6.4.3.3. Regulatory framework
      • 6.4.3.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Competitive scenario
      • 6.4.4.3. Regulatory framework
      • 6.4.4.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Competitive scenario
      • 6.4.5.3. Regulatory framework
      • 6.4.5.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Competitive scenario
      • 6.4.6.3. Regulatory framework
      • 6.4.6.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Competitive scenario
      • 6.4.7.3. Regulatory framework
      • 6.4.7.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Competitive scenario
      • 6.4.8.3. Regulatory framework
      • 6.4.8.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Competitive scenario
      • 6.4.9.3. Regulatory framework
      • 6.4.9.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Competitive scenario
      • 6.5.4.3. Regulatory framework
      • 6.5.4.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Competitive scenario
      • 6.5.5.3. Regulatory framework
      • 6.5.5.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Competitive scenario
      • 6.5.6.3. Regulatory framework
      • 6.5.6.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Competitive scenario
      • 6.5.7.3. Regulatory framework
      • 6.5.7.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. Pfizer Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Service benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Novartis AG
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Service benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Icon Plc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Service benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Laboratory Corporation of America
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Service benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. AbbVie Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Service benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Cadila Healthcare Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Service benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Takeda Pharmaceuticals
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Service benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Eli Lilly and Company
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Service benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novo Nordisk A/S
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Service benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Gilead Sciences Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Service benchmarking
      • 7.3.10.4. Strategic initiatives